U.S. In Vitro Diagnostics Market worth 25.99 Billion USD by 2020 U.S. In Vitro Diagnostics Market worth 25.99 Billi | Page 15

TABLE OF CONTENTS
9
U. S. IN VITRO DIAGNOSTICS MARKET, BY END USER............................................................. 74
• 9.1
INTRODUCTION............................................................................................................................................................... 75
• 9.2
HOSPITAL LABORATORIES.............................................................................................................................................. 76
• 9.3
CLINICAL / INDEPENDENT LABORATORIES...................................................................................................................... 77
• 9.3.1
LARGE LABORATORIES / REFERENCE LABORATORIES................................................................................... 80
• 9.3.2
MEDIUM-SIZED LABORATORIES................................................................................................................... 80
• 9.3.3
SMALL LABORATORIES................................................................................................................................. 80
• 9.4
OTHER END USERS.......................................................................................................................................................... 81
10
COMPETITIVE LANDSCAPE....................................................................................................... 83
• 10.1
OVERVIEW........................................................................................................................................................................ 83
• 10.2
MARKET SHARE ANALYSIS............................................................................................................................................. 85
• 10.3
COMPETITIVE SITUATION AND TRENDS......................................................................................................................... 87
• 10.3.1
NEW PRODUCT LAUNCHES.......................................................................................................................... 87
• 10.3.2
COLLABORATIONS, AGREEMENTS, & PARTNERSHIPS................................................................................ 88
• 10.3.3
APPROVALS................................................................................................................................................... 89
• 10.3.4
MERGERS & ACQUISITIONS......................................................................................................................... 90
• 10.3.5
OTHERS......................................................................................................................................................... 91
11
COMPANY PROFILES................................................................................................................. 92
•( Overview, Financials, Products & Services, Strategy, & Developments)*
• 11.1
ABBOTT LABORATORIES, INC.......................................................................................................................................... 93
• 11.2
DANAHER CORPORATION................................................................................................................................................ 97
• 11.3
JOHNSON AND JOHNSON............................................................................................................................................. 103
• 11.4
ROCHE DIAGNOSTICS................................................................................................................................................... 106
• 11.5
SIEMENS HEALTHCARE................................................................................................................................................. 112
• 11.6
BECTON, DICKINSON AND COMPANY.......................................................................................................................... 118
• 11.7
BIOMÉRIEUX.................................................................................................................................................................. 123
• 11.8
BIO-RAD LABORATORIES, INC....................................................................................................................................... 128
• 11.9
SYSMEX CORPORATION................................................................................................................................................ 133
• 11.10
THERMO FISHER SCIENTIFIC, INC................................................................................................................................ 139
• 11.11
QIAGEN N. V.................................................................................................................................................................... 145
• * Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
sales @ marketsandmarkets. com www. marketsandmarkets. com
15